- Home
- BCRX vs NTLA Comparison
BCRX vs NTLA Comparison
Compare BCRX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- NTLA
- Stock Information
- Founded
- BCRX 1986
- NTLA 2014
- Country
- BCRX United States
- NTLA United States
- Employees
- BCRX N/A
- NTLA N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCRX Health Care
- NTLA Health Care
- Exchange
- BCRX Nasdaq
- NTLA Nasdaq
- Market Cap
- BCRX 1.4B
- NTLA 1.2B
- IPO Year
- BCRX 1994
- NTLA 2016
- Fundamental
- Price
- BCRX $6.87
- NTLA $9.02
- Analyst Decision
- BCRX Strong Buy
- NTLA Buy
- Analyst Count
- BCRX 11
- NTLA 20
- Target Price
- BCRX $19.00
- NTLA $25.48
- AVG Volume (30 Days)
- BCRX 7.8M
- NTLA 10.0M
- Earning Date
- BCRX 11-03-2025
- NTLA 11-06-2025
- Dividend Yield
- BCRX N/A
- NTLA N/A
- EPS Growth
- BCRX N/A
- NTLA N/A
- EPS
- BCRX N/A
- NTLA N/A
- Revenue
- BCRX $599,816,000.00
- NTLA $52,857,000.00
- Revenue This Year
- BCRX $41.57
- NTLA $8.51
- Revenue Next Year
- BCRX $6.25
- NTLA N/A
- P/E Ratio
- BCRX N/A
- NTLA N/A
- Revenue Growth
- BCRX 45.38
- NTLA 14.99
- 52 Week Low
- BCRX $6.00
- NTLA $5.90
- 52 Week High
- BCRX $11.31
- NTLA $28.25
- Technical
- Relative Strength Index (RSI)
- BCRX 43.58
- NTLA 30.14
- Support Level
- BCRX $6.51
- NTLA $12.15
- Resistance Level
- BCRX $7.22
- NTLA $13.69
- Average True Range (ATR)
- BCRX 0.27
- NTLA 1.51
- MACD
- BCRX 0.01
- NTLA -1.33
- Stochastic Oscillator
- BCRX 41.15
- NTLA 0.90
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.